DOCSLIB.ORG

Nicox Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nicox Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis PRESS RELEASE NicOx initiates two large ABPM studies for naproxcinod in hypertensive patients with osteoarthritis March 3, 2008. Sophia Antipolis, France. www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced the initiation of two large clinical pharmacology studies in the United States, which will assess the blood pressure profile of naproxcinod in comparison to ibuprofen and naproxen, using the Ambulatory Blood Pressure Monitoring (ABPM) technique. These separate studies, 12 and 16 weeks in duration, will together recruit a total of around 420 osteoarthritis patients with controlled hypertension and results are projected in Q4 2008. Naproxcinod is NicOx’ lead investigational drug and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is currently in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis, with results of the last two phase 3 studies anticipated in the second half of 2008. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen and naproxen, are commonly used by osteoarthritis patients to control their chronic pain, inflammation and stiffness and significantly improve quality of life for millions of people. However, these important products have the tendency to raise blood pressure to an extent that may increase the rate of serious cardiovascular adverse events (see NOTE 1). Pascal Pfister MD, Chief Scientific Officer and Head of Research and Development at NicOx, said: “Our development program for naproxcinod aims to address the safety concerns surrounding anti-inflammatory agents and blood pressure, which represents a serious medical issue. Previous studies using the ABPM technique and Office Blood Pressure Measurements have suggested that naproxcinod may have an improved blood pressure profile compared to existing anti-inflammatory drugs, which would greatly facilitate its future adoption by physicians and patients. These two new studies will provide important data in a relevant population of chronically treated osteoarthritis patients and should add additional weight to the consistent data we are accumulating on naproxcinod’s blood pressure profile.” The objectives of these new ABPM studies (see NOTE 2) are to provide important additional data on the 24-hour blood pressure profile of naproxcinod in chronically treated osteoarthritis patients, in comparison to commonly used Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). These data should complement the promising results of a 2-week ABPM study for naproxcinod in healthy volunteers with hypertension (the 104 study), which were presented at the American Heart Association (AHA) in November 2007 (see press release of November 7, 2007). They will also complement the Office Blood Pressure Measurements (OBPMs) being collected in each of the pivotal phase 3 osteoarthritis studies (including the completed 301 study and the ongoing 302 and 303 studies – for full details see the financial results press release issued today). Design of the 111 and 112 ABPM studies · The 111 study is a 12-week, phase 1, double-blind, parallel group, exploratory trial, where approximately 120 patients will be enrolled at around 30 clinical sites in the United States. Patients will have a minimum age of 40 and be diagnosed with controlled essential hypertension and osteoarthritis, with at least one hip or knee involved. After a one week screening period, patients will be randomized to one of two groups, which will receive increasing doses of either naproxcinod or naproxen at three week intervals. 24-Hour blood pressure monitoring will be conducted at baseline and at the end of each three-week dose escalation, using an ABPM device (see NOTE 2). · The 112 study is a 16-week, phase 1, double-blind, parallel group, exploratory trial, where approximately 300 patients will be recruited at around 60 clinical sites in the United States. As in the 111 study, patients will be 40 years, or older, with osteoarthritis in at least one hip or knee and a diagnosis of controlled essential hypertension. Following a one week screening period, patients will be randomized to either one of five groups, which will receive 13 weeks of treatment with: naproxcinod 375 mg bid (twice daily), naproxcinod 750 mg bid, naproxen 250 mg bid, naproxen 500 mg bid or ibuprofen 600 mg tid. At the end of the treatment period, all patients will receive placebo for 2 weeks. 24-Hour blood pressure monitoring will be conducted at baseline and at the end of the 13-week treatment period. The primary objective of the study is to assess the mean change from baseline in the average 24-hour systolic blood pressure, as well as evaluating the general safety and tolerability of naproxcinod. Staffan Strömberg, Vice President of Drug Development at NicOx, said: “We have chosen naproxen as the comparator in the pivotal phase 3 studies, due to its well established anti-inflammatory efficacy and its perception as the least risky of the existing NSAIDs in terms of blood pressure and cardiovascular safety. In the 112 study, we will also obtain long term 24-hour blood pressure comparisons between our first CINOD and ibuprofen, the most widely used NSAID.” NicOx S.A., 1 Les Taissounières – Bât HB4 – 1681 route des Dolines - BP313, 06906 Sophia Antipolis cedex, France. Tel. +33 (0)4 97 24 53 00 • Fax +33 (0)4 97 24 53 99 NOTE 1: The biological mechanisms by which NSAIDs increase blood pressure are not well understood, although an increase in blood vessel constriction, interference with antihypertensive treatment and retaining dietary salt all seem to contribute. The extent of the increase is not fully defined, although there appears to be a variation between different products, with ibuprofen and the selective COX-2 inhibitors bringing about greater increases than non-selective drugs, such as naproxen. However, all existing products have been associated with some blood pressure increase. Both treated hypertensive patients and individuals with normal blood pressure appear to be affected and the dose and duration of administration also seems to be important, with hypertension occurring more frequently with chronic treatment. NOTE 2: Ambulatory Blood Pressure Measurement (ABPM) involves using a portable device to independently measure and record blood pressure at frequent intervals over a 24-hour period with minimal disruption of a subject’s daily activity. In these new studies, blood pressure measurements will be taken at 20-minute intervals between 6:00 am and 10:00 pm and every hour from 10:01 pm to 5:59 am. NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease. Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008. Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, glaucoma and Chronic Obstructive Pulmonary Disease (COPD). NicOx S.A. is headquartered in France and is listed on the Euronext Paris Stock Exchange (Compartment B: Mid Caps). This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of NicOx S.A. to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Document de Reference filed with the AMF, which is available on the AMF website (http://www.amf- france.org) or on NicOx S.A.'s website (http://www.nicox.com). CONTACTS: http://www.nicox.com NicOx: Karl Hanks • Director of Investor Relations and Corporate Communications • Tel +33 (0)4 97 24 53 42 • [email protected] Investors in the United States - Burns McClellan: Lisa Burns • [email protected] Juliane Snowden • Tel +1 212 213 0006 • [email protected] Media in the United States - FD: Jonathan Birt • Tel +1 212 850 56 34 • [email protected] Media in Europe - Citigate Dewe Rogerson: David Dible • Tel +44 (0)207 282 2949 • [email protected] Sylvie Berrebi • Tel +44(0) 20 7282 1050 • [email protected] NicOx S.A., 2 Les Taissounières – Bât HB4 – 1681 route des Dolines - BP313, 06906 Sophia Antipolis cedex, France. Tel. +33 (0)4 97 24 53 00 • Fax +33 (0)4 97 24 53 99 .
Load more

Recommended publications
  • Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs: from Pathogenesis to Clinical Practice
    ARTIGO DE REVISÃO Hypersensitivity to nonsteroidal anti-inflammatory drugs: From pathogenesis to clinical practice Hipersensibilidade a anti-inflamatórios não esteroides: Da patogénese à prática clínica Data de receção / Received in: 28/10/2017 Data de aceitação / Accepted for publication in: 17/11/2017 Rev Port Imunoalergologia 2018; 26 (3): 207-220 Inês Mota, Ângela Gaspar, Mário Morais-Almeida Imunoallergy Department, CUF Descobertas Hospital, Lisbon ABSTRACT Nonsteroidal anti - inflammatory drugs (NSAIDs) are one of the leading causes of hypersensitivity reactions, which affect a considerable percentage of the general population. These drugs can induce a wide spectrum of reactions with distinct timing, organ involvement and severity, including either immunological or nonimmunological mechanisms. A proper diagnosis can be particularly challenging since most reactions result from the pharmacological mechanism of the drug and might be dose - dependent. The clinical classification of NSAIDs - induced reactions has changed over time. Accurate diagnosis depends on strict clinical history and proper understanding of underlying mechanism. Skin testing and in vitro testing have limited usefulness. Drug chal- lenge tests with the culprit or alternative drugs are the gold standard for the diagnosis, and provide information about drug avoidance and safe therapeutic options. In selected cases drug desensitization might be a therapeutic option. In this review, we will attempt to highlight the main aspects to be taken into account for a proper management of patients with NSAIDs hyper- sensitivity. Key - words: Acetylsalicylate acid, alternative drugs, desensitization, diagnosis, hypersensitivity, nonsteroidal anti - inflammatory drugs. 207 REVISTA PORTUGUESA DE IMUNOALERGOLOGIA Inês Mota, Ângela Gaspar, Mário Morais-Almeida RESUMO Os anti - inflamatórios não esteroides (AINEs) são uma das principais causas de reações de hipersensibilidade, afetando uma percentagem considerável da população em geral.
    [Show full text]
  • Nicox Gives Full Details of Naproxcinod Phase 3 Plan in Osteoarthritis and an Update on Other R&D Programs
    PRESS RELEASE NicOx gives full details of naproxcinod phase 3 plan in osteoarthritis and an update on other R&D programs September 6, 2006. Sophia Antipolis, France. www.nicox.com NicOx S.A. (Eurolist: NICOX) is today announcing the full details of the phase 3 clinical program it has designed to gain regulatory approval for naproxcinod (HCT 3012) for treating the signs and symptoms of osteoarthritis (OA) in the United States (US) and Europe. The plan consists of three phase 3 efficacy trials, the first of which is currently ongoing in knee OA in the US, with an additional, similarly designed knee OA study expected to start in the first quarter of 2007. This will be followed by the initiation of a hip OA trial in the third quarter of 2007. NicOx is also providing details of its recent interactions with regulatory authorities for naproxcinod. In addition, NicOx is providing new information on the clinical studies it plans to conduct to confirm naproxcinod’s superior blood pressure control and gastrointestinal safety and tolerability profile, compared to existing anti-inflammatory agents. Summary of additional disclosures being made today: · Initiation of an important new development program for NCX 6560, a nitric oxide-donating statin derivative with broadened activity for the treatment of high risk cardiovascular patients (see separate press release) · New results from two clinical studies for NCX 4016, which support the rationale for develop ing this compound for the treatment of type 2 diabetes · Disclosure that the first results from
    [Show full text]
  • Nicox' Naproxcinod Shows Robust Blood Pressure Results in Phase 3
    PRESS RELEASE NicOx’ naproxcinod shows robust blood pressure results in phase 3 pooled analysis First compound in the CINOD class shows similar blood pressure profile to placebo, with clear differentiation from a widely used NSAID December 17, 2008. Sophia Antipolis, France. www.nicox.com NicOx S.A. (NYSE Euronext Paris: COX) today announced positive results of a pre-specified pooled analysis of 2,734 patients with osteoarthritis (OA) from the 301, 302 and 303 pivotal phase 3 studies for naproxcinod. Both doses of naproxcinod showed a significant reduction in systolic and diastolic blood pressure (SBP and DBP) compared to naproxen 500 mg bid over the whole 13 week period (p<0.001 for naproxcinod 750 mg bid and p <0.05 for naproxcinod 375 mg bid). Naproxcinod is the first compound in a novel class of anti-inflammatory agents known as Cyclooxygenase-Inhibiting Nitric Oxide Donators (CINODs). A significantly lower proportion of patients on naproxcinod experienced an increase in SBP of 5 mmHg or more, compared to naproxen Over the whole 13 week period the proportion of patients whose SBP increased by 5 mmHg or more was higher for naproxen 500 mg bid, as compared to naproxcinod 750 mg bid (p<0.001), naproxcinod 375 mg bid (p=0.013) and placebo (p<0.001). Both naproxcinod doses showed a similar blood pressure profile to placebo, in contrast to naproxen which raised SBP (p<0.001) There is a clear unmet medical need for a novel anti-inflammatory agent with no detrimental impact on blood pressure. COX-2 inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs), such as naproxen, are widely used for the symptomatic treatment of OA but can lead to the onset of new episodes of high blood pressure or worseni ng of pre-existing hypertension.
    [Show full text]
  • Efficacy, Safety, and Tolerability of the Cyclooxygenase-Inhibiting Nitric
    Efficacy, Safety, and Tolerability of the Cyclooxygenase-Inhibiting Nitric Oxide Donator Naproxcinod in Treating Osteoarthritis of the Hip or Knee JON KARLSSON, ALDINA PIVODIC, DIANA AGUIRRE, and THOMAS J. SCHNITZER ABSTRACT. Objective. Naproxcinod, a cyclooxygenase-inhibiting nitric oxide donator antiinflammatory drug, was evaluated in this phase 2, double-blind, randomized, parallel group study to determine its opti- mal dose in patients with osteoarthritis (OA). Methods. In total 543 patients with OA of the hip or knee were randomized to receive naproxcinod 750 mg once daily (qd), 750 mg twice daily (bid), 1125 mg bid, rofecoxib 25 mg qd, or placebo for 6 weeks. The primary efficacy variable was the within-patient change from baseline to the average of Weeks 4 and 6 in WOMAC™ pain subscale score. Treatment-group differences were compared using ANCOVA with factors for treatment and country, and baseline pain subscale score as a covari- ate. Safety endpoints included vital signs and adverse events. Treatment-group differences in mean change from baseline to Week 6 in systolic blood pressure (SBP) were compared using an ANCOVA with treatment and country as fixed factors and baseline SBP as covariate. Results. All active treatments showed statistically significant reductions in WOMAC pain score compared to placebo (p ≤ 0.02). Naproxcinod was well tolerated. The 750 mg bid dose appeared to have the best balance of benefit versus safety. All 3 naproxcinod doses showed a reduction in SBP, while an increase was shown for rofecoxib. The changes for the naproxcinod groups were statisti- cally significantly better compared to rofecoxib (p ≤ 0.02).
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Naproxcinod Shows Significant Advantages Over Naproxen in The
    Miglietta et al. Orphanet Journal of Rare Diseases (2015) 10:101 DOI 10.1186/s13023-015-0311-0 RESEARCH Open Access Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy Daniela Miglietta1†, Clara De Palma2*†, Clara Sciorati3, Barbara Vergani4, Viviana Pisa2, Antonello Villa4, Ennio Ongini1 and Emilio Clementi2,5 Abstract Background: In dystrophin-deficient muscles of Duchenne Muscular Dystrophy (DMD) patients and the mdx mouse model, nitric oxide (NO) signalling is impaired. Previous studies have shown that NO-donating drugs are beneficial in dystrophic mouse models. Recently, a long-term treatment (9 months) of mdx mice with naproxcinod, an NO-donating naproxen, has shown a significant improvement of the dystrophic phenotype with beneficial effects present throughout the disease progression. It remains however to be clearly dissected out which specific effects are due to the NO component compared with the anti-inflammatory activity associated with naproxen. Understanding the contribution of NO vs the anti-inflammatory effect is important, in view of the potential therapeutic perspective, and this is the final aim of this study. Methods: Five-week-old mdx mice received either naproxcinod (30 mg/kg) or the equimolar dose of naproxen (20 mg/kg) in the diet for 6 months. Control mdx mice were used as reference. Treatments (or vehicle for control groups) were administered daily in the diet. For the first 3 months the study was performed in sedentary animals, then all mice were subjected to exercise until the sixth month. Skeletal muscle force was assessed by measuring whole body tension in sedentary animals as well as in exercised mice and resistance to fatigue was measured after 3 months of running exercise.
    [Show full text]
  • Nicox' Naproxcinod Phase 3 Results Presented at American College Of
    PRESS RELEASE NicOx’ naproxcinod phase 3 results presented at American College of Rheumatology November 12, 2007. Sophia Antipolis, France. www.nicox.com NicOx S.A. (Eurolist: COX) today announced that results from the first pivotal phase 3 trial for naproxcinod in patients with osteoarthritis of the knee (the 301 study) were presented on November 10, 2007 at the 71st annual meeting of the American College of Rheumatology (ACR), in Boston, Massachusetts (see NOTE). Naproxcinod is NicOx’ lead investigational drug product and the first compound in the COX-Inhibiting Nitric Oxide Donator (CINOD) class. The presentation contained additional efficacy data to the top-line results announced in 2006 (see press release of October 27, 2006) which showed that naproxcinod met all three co-primary endpoints of the trial. The data showed that both doses of naproxcinod (750 mg and 375 mg bid) had superior efficacy to placebo at all time points (2, 6 and 13 weeks). This presentation also contained additional safety and tolerability information, including the gastro-intestinal adverse event rates and blood pressure measurements reported for each of the treatment groups. Detailed clinical data from the 301 study were presented, including data for each of the three co-primary efficacy endpoints: WOMACTM pain subscale, WOMACTM function subscale and patients’ overall rating of disease status. Each of the active treatments (naproxcinod 750 mg, naproxcinod 375 mg and naproxen 500 mg bid) were statistically significantly superior to placebo (p<=0.0002) at 2, 6 and 13 weeks. In addition, standard quality of life scores showed a functional improvement for both naproxcinod doses, as well as for the naproxen group.
    [Show full text]
  • WO 2014/111957 Al 24 July 2014 (24.07.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/111957 Al 24 July 2014 (24.07.2014) P O P C T (51) International Patent C (81) Designated States (unless otherwise indicated, for every C07C 203/04 (2006.01) A61P 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/216 (2006.01) A61P 1/04 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/621 (2006.01) A61P 25/24 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61P 35/00 (2006.01) A61P 25/08 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61P 29/00 (2006.01) A61P 31/04 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, A61P 29/02 (2006.01) A61P 33/06 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, A61P 3/06 (2006.01) A61P 39/06 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, A61P 3/10 (2006.01) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (21) International Application Number: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, PCT/IN20 14/000033 ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 17 January 2014 (17.01 .2014) kind of regional protection available): ARIPO (BW, GH, (25) Filing Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (26) Publication Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (30) Priority Data: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, FT, LT, LU, LV, 181/MUM/2013 2 1 January 2013 (21 .01 .2013) IN MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (72) Inventor; and KM, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]
  • Beprana, INN-Naproxcinod
    EMA/657046/2011 Committee for Medicinal Products for Human Use (CHMP) Assessment report Beprana naproxcinod Procedure No.: EMEA/H/C/002159/ Applicant: NicOX S.A Note Rapporteurs’ day 180 joint assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. This should be read in conjunction with the “Question and Answer” document on the withdrawal of the application: the Assessment Report may not include all available information on the product if the CHMP assessment of the latest submitted information was still ongoing at the time of the withdrawal of the application. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged. TABLE OF CONTENTS EXECUTIVE SUMMARY ................................................................................. 6 Problem statement ................................................................................................... 6 About the product..................................................................................................... 6 The development programme/Compliance with CHMP Guidance/Scientific Advice............ 7 General comments on compliance with GMP, GLP, GCP .................................................. 7 Type of application and other comments on the submitted dossier ..................................
    [Show full text]
  • Naproxcinod for the Second Line Treatment of Osteoarthritis
    NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Single Technology Appraisal (STA) Naproxcinod for the second line treatment of osteoarthritis Provisional matrix of consultees and commentators Consultees Commentators (no right to submit or appeal) Manufacturers/sponsors General • NicOx (naproxcinod) • Board of Community Health Councils in Wales Patient/carer groups • British National Formulary • Action on Pain • Care Quality Commission • Afiya Trust • Commissioning Support Appraisals • Arthritic Association Service • Arthritis & Musculoskeletal Alliance • Department of Health, Social Services (ARMA) and Public Safety for Northern Ireland • Arthritis Care • Medicines and Healthcare products • Black Health Agency Regulatory Agency • Carers UK • National Association of Primary Care • Chinese National Healthy Living • NHS Alliance Centre • NHS Commercial Medicines Unit • Counsel and Care • NHS Confederation • Equalities National Council • NHS Quality Improvement Scotland • Leonard Cheshire Disability • Public Health Wales NHS Trust • Muslim Council of Great Britain • Scottish Medicines Consortium • Muslim Health Network • National Osteoporosis Society Possible comparator manufacturer(s) • Pain Concern • A .Menarini Pharma UK SRL • Pain Relief Foundation (ketoprofen) • RADAR - Royal Association for • Abbot Laboratories (ibuprofen, Disability and Rehabilitation flurbiprofen) • Skill: National Bureau for Students • Actavis UK (ibuprofen, ketoprofen, with Disabilities piroxicam, naproxen, fenbufen, • South Asian Health Foundation
    [Show full text]
  • WO 2017/137762 Al 17 August 2017 (17.08.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/137762 Al 17 August 2017 (17.08.2017) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 9/14 (2006.01) A61K 31/192 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/GB20 17/050345 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 10 February 20 17 (10.02.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 1602579.3 12 February 2016 (12.02.2016) GB GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventor; and TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant MIHRANYAN, Albert [SE/SE]; DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Geijersgatan 40B, SE-752 26 Uppsala (SE).
    [Show full text]